Who
Julia Marie Eastland
Director
Company insider
Files Form 4 as: Director, Lantheus Holdings; CEO & President, Zentalis Pharmaceuticals; Director, Dynavax Technologies; President and CEO, Harpoon Therapeutics; Director, CalciMedica; CFO & Cbo, Cascadian Therapeutics.
In numbers
- Trades disclosed
- 73
- Buys
- 1
- Sells
- 2
- Bought
- $49K
- Sold
- $42K
- Companies
- 6
- Companies where not an officer
- 3
- First trade
- 10 Nov 2010
- Last trade
- 14 May 2026
- Last filed
- 18 May 2026
Companies traded
Activity over time
1 Jan 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 14 May 2026filed 18 May 2026 | LNTH Lantheus HoldingsDiagnostics & Labs | SEC FORM 4 Code A | —4,137 at $0.00 | filing |
| 14 May 2026filed 18 May 2026 | LNTH Lantheus HoldingsDiagnostics & Labs | SEC FORM 4 Code A | —4,137 at $0.00 | filing |
| 9 Feb 2026filed 10 Feb 2026 | ZNTL Zentalis PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $2,127889 at $2.39 | filing |
| 9 Feb 2026filed 10 Feb 2026 | ZNTL Zentalis PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $2,125889 at $2.39 | filing |
| 6 Feb 2026filed 10 Feb 2026 | ZNTL Zentalis PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $19K7,866 at $2.43 | filing |
| 6 Feb 2026filed 10 Feb 2026 | ZNTL Zentalis PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $19K7,866 at $2.43 | filing |
| 8 Jan 2026filed 9 Jan 2026 | ZNTL Zentalis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —775,000 at $0.00 | filing |
| 8 Jan 2026filed 9 Jan 2026 | ZNTL Zentalis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —775,000 at $0.00 | filing |
| 14 May 2025filed 16 May 2025 | LNTH Lantheus Holdingsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —4,543 at $0.00 | filing |
| 14 May 2025filed 16 May 2025 | LNTH Lantheus HoldingsDiagnostics & Labs | SEC FORM 4 Code A | —2,537 at $0.00 | filing |
| 3 Feb 2025filed 5 Feb 2025 | ZNTL Zentalis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —59,388 at $0.00 | filing |
| 3 Feb 2025filed 5 Feb 2025 | ZNTL Zentalis PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —59,388 at $0.00 | filing |
| 31 Jan 2025filed 4 Feb 2025 | ZNTL Zentalis PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $49K28,500 at $1.73 | filing |
| 2 Dec 2024filed 3 Dec 2024 | ZNTL Zentalis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,028,800 at $0.00 | filing |
| 10 Sep 2024filed 12 Sep 2024 | LNTH Lantheus Holdingsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —2,506 at $0.00 | filing |
| 10 Sep 2024filed 12 Sep 2024 | LNTH Lantheus HoldingsDiagnostics & Labs | SEC FORM 4 Code A | —1,345 at $0.00 | filing |
| 23 May 2024filed 28 May 2024 | Dynavax Technologiesoption or derivative | SEC FORM 4 Code A | —22,500 at $0.00 | filing |
| 23 May 2024filed 28 May 2024 | Dynavax Technologies | SEC FORM 4 Code A | —5,357 at $0.00 | filing |
| 11 Mar 2024filed 11 Mar 2024 | Harpoon Therapeuticsoption or derivative | SEC FORM 4 Code D | —2,765 | filing |
| 11 Mar 2024filed 11 Mar 2024 | Harpoon Therapeuticsoption or derivative | SEC FORM 4 Code D | —40,759 | filing |
News
Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 AbstractZNTL · manilatimes.net · 18 Oct 2026
0 headlines in the last 90 days name Julia Marie Eastland; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.